Oncotarget. 2024 Aug 26;15:588-589. doi: 10.18632/oncotarget.28639.
Artificial intelligence (AI) is revolutionizing society and healthcare, offering new possibilities for precision medicine. Immunotherapy in oncology (IO) has similarly transformed cancer treatment through novel mechanisms of therapeutic action, but has also led to atypical response patterns that challenge traditional methods for response evaluation. This editorial explores the role of AI in addressing these challenges through the development of new biomarkers for precise disease characterization, and in particular those built on imaging for the early response assessment of patients diagnosed with cancer and treated with IO. Properly leveraged AI-based techniques could herald a new era of precision medicine guided by non-invasive, imaging-based disease evaluation.
人工智能(AI)正在彻底改变社会和医疗保健行业,为精准医学提供新的可能。肿瘤学中的免疫疗法(IO)也通过新的治疗作用机制改变了癌症治疗,但也导致了非典型的反应模式,对传统的反应评估方法提出了挑战。这篇社论探讨了 AI 通过开发新的生物标志物来精确描述疾病,特别是那些基于成像的方法,用于评估接受 IO 治疗的癌症患者的早期反应,从而在应对这些挑战中所发挥的作用。恰当利用基于 AI 的技术可能预示着一个新的精准医学时代的到来,这个时代将以基于成像的非侵入性疾病评估为指导。